

Goldman Sachs International

Compliance Operations Department

| Peterborough Court | 133 Fleet Street | London, EC4A 2BB |

CONFIDENTIALITY NOTE: The information contained in this facsimile message (Afax@) is sent by an attorney or his/her agent and is intended only for the confidential use of the above named recipient. The information may be protected by attorney / client privilege or other legal rules. If the reader of this message is not the intended recipient or the person responsible for delivering it to the intended recipient, you are hereby notified that you have received this communication in error, and that any review, dissemination, distribution or copying of this communication is strictly prohibited. If you have received this fax in error, please notify the sender immediately by telephone at the number set forth above and destroy this facsimile message. Thank you.

To: Banking, Finance and Insurance Commission
Fax No: +32 2 220 59 03
Attn: Mr. G. Delaere

From: Joanne Wall
Date: 18 April 2007
Tel: +44 (0) 207-051-1704
Email -- joanne.wall@gs.com

Please do not separate this cover sheet from the attached disclosure.

CHAPTER I - LAW OF 2 MARCH 1989

Form A: initial declaration of interest held in a listed company

Please find attached a copy of The Goldman Sachs Group, Inc's Subsequent declaration of interest in Omega Pharma NV.

cc.

Company Secretary - Omega Pharma NV
Telefax: (0032) (0)9 381 02 20
Mr. Sam Sabbe, Chief Financial Officer (CFO)
Mr. Jan Peeters, Chief Financial Officer (CFO) Arseus
eMail: sabine.vancoppenolle@omega-pharma.be,
info@omega-pharma.be

Number of pages transmitted including cover page: 5

Please ring +44 (0) 207-051-1704 if you do not receive all pages.

Regulated & Authorized by The Financial Services Authority

CHAPTER I - LAW OF 2 MARCH 1989

Form A: initial declaration of interest held in a listed company**0. To be sent to:**

- the listed company concerned
- Banking, Finance and Insurance Commission
Supervision of Financial Information and Markets
For the attention of Mr. G. Delaere
Rue du Congrès 12-14, 1000 BRUSSELS - BELGIUM
Fax: +32 2 220 59 03 – e-mail: fmi.fin@cbfa.be

1. Name of company concerned : Omega Pharma NV**2. Details of the person making the declaration¹ in the capacity as declarant acting for own account / in the capacity as declarant acting on behalf of a third party² / ~~in the capacity as agent³~~****a) natural person**

surname + first name
address

Wall, Joanne
Goldman Sachs International
Peterborough Court, 133 Fleet Street, London,
EC4A 2BB
+44 (0) 20 7051 1704

phone number (optional)

b) legal person

legal form + company name
registered office

Goldman Sachs Group, Inc
85 Broad Street, New York, NY 10004, USA

phone number

+44 (0) 20 7051 1704

fax number

+44 (0) 20 7774 4859

name and capacity of the

Joanne Wall

signatory of the declaration

Executive Director, Compliance Operations

3. Items covered by the declarationPreliminary remarks

Where the declaration is made by related persons or persons acting in concert, tables I and II shall be completed as many times as necessary:

- first for each of these persons *separately*, even where none of them reach a threshold as defined by law (see Article 8, § 1, 3°, of the Royal Decree of 10 May 1989)⁴;
- then for the *group* of related persons or persons acting in concert (see Article 2, §§ 1 and 2, of the Law of 2 March 1989).

¹ Cross out what is not appropriate.

² I.e. where a third party holds rights for the account of another person.

³ Each time a person who is subject to declaration entrusts this task to another person.

⁴ Except in the case of natural persons acting in concert none of whom possess a number of securities representing 5% or more of effective voting rights: these may make a joint declaration, without indicating the individual holders (Article 2, § 3, paragraph 2, of the Law of 2 March 1989).

Table I : general information

Name of the company concerned	Omega Pharma NV
Rights held by / for the account of ¹ (cross out what is not appropriate)	Please see Appendix A Goldman Sachs Group, Inc 85 Broad Street, New York, NY 10004, USA
Related to	Please refer to Appendix A
Acting in concert with	Not applicable
Date of completion of the situation giving rise to the declaration	16 April 2007
Sources relating to the denominator	Company website

¹ Where a third party holds rights for the account of another person.

* For natural persons: surname and first name + address; for legal persons: legal form, company name and address of registered office.

Table II : calculation of the stake

	denominator (a)	numerator (b)	% (b/a)
1. Effective voting rights attaching to securities <ul style="list-style-type: none"> • representing the capital • not representing the capital 	26,146,641	1,542,436	5.90
2. Future voting rights , potential or not, resulting from <ul style="list-style-type: none"> • rights and commitments for conversion into or subscription of securities to be issued, viz.: <ul style="list-style-type: none"> (x) bond conversions ◇ loan conversions ◇ exercise of warrants ◇ others (give details as appropriate) • rights and commitments for acquisition of issued securities, viz.: <ul style="list-style-type: none"> ◇ options ◇ warrants relating to issued securities ◇ commitments arising from a contract ◇ others (give details as appropriate) 			
Total	26,146,641	1,542,436	5.90
Mention Rights and commitments for conversion into, subscription of or acquisition of securities, subject to conditional clauses: <ul style="list-style-type: none"> • bond conversion • exercise of warrants • others (give details as appropriate) 			
For rights and commitments from which future voting rights may arise, please specify the waiting or exercise period			

4. **Additional information to be provided if the number of securities held is equal to or greater than 20 %** (see Article 8, paragraph 3 of the Royal Decree of 10 May 1989)


a. Description of the overall strategy in the course of which the acquisition is made:

b. Number of securities acquired during the 12 months preceding this declaration, and manner of acquisition:

	number	manner of acquisition
1. Effective voting rights attaching to securities <ul style="list-style-type: none"> • representing capital • not representing capital 		
2. Future voting rights , potential or not, resulting from <ul style="list-style-type: none"> • rights or commitments for conversion into or subscription of securities to be issued, viz.: <ul style="list-style-type: none"> ◊ bond conversions ◊ loan conversions ◊ exercise of warrants ◊ others (give details as appropriate) • rights and commitments for subscription or acquisition of issued securities, viz.: <ul style="list-style-type: none"> ◊ options ◊ warrants relating to issued securities ◊ commitments arising from a contract ◊ others (give details as appropriate) 		

5. **Description, possibly in the form of an organizational chart, of the structure of control of the company(ies) subject to declaration (optional)**

Done on 18 April 2007 in London



 Joanne Wall
 (signature)

Annexes to be sent only to the Banking, Finance and Insurance Commission (mandatory by virtue of Article 4, § 1, paragraph 1, of the Law of 2 March 1989): the documents relating to the operation(s) giving rise to the declaration.

Appendix A

This appendix provides a detailed breakdown of the positions held across the Goldman Sachs Group, Inc.

We hereby notify you that as at close of business on 16 April 2007, The Goldman Sachs Group, Inc., ("GS Inc") of 85 Broad Street, New York, NY 10004, USA, was interested, by attribution only, in a total of 1,542,436 shares.

Goldman Sachs & Co held beneficially 624 (0.00%)

Goldman Sachs International held beneficially 81,873 (0.31%)

Goldman Sachs Asset Management International held beneficially 234,441 (0.90%)

Goldman Sachs Asset Management LP held beneficially 1,225,498 (4.69%)